stocktitan.net

Upstream Bio Phase 2 Trial Shows Verekitug Cuts Severe Asthma Flares 56%

Upstream Bio logoUpstream Bio
Sig3.03Sen+6.08Env+0.10Soc+4.00Gov+0.65

Upstream Bio presented Phase 2 VALIANT results for verekitug in severe asthma at ERS Congress 2026. Dosing 100 mg every 12 weeks reduced AAER by 56% versus placebo in patients with severe asthma, with favorable safety and improvements in lung function and inflammatory biomarkers. The company plans to start Phase 3 in severe asthma and CRSwNP in Q1 2027.

Coverage (2)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro